Matinas BioPharma Holdings, Inc. (MTNB) Stock Score, Valuation & Financial Research

Matinas BioPharma Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MTNB

Matinas BioPharma Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.70. These figures are a research snapshot, not a buy or sell recommendation.

What Matinas BioPharma Holdings, Inc. does

Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Matinas BioPharma is a clinical-stage biopharmaceutical company that historically focused on developing therapies using its proprietary lipid nanocrystal (LNC) platform delivery technology. The company currently operates under a cost-cutting strategy, having paused internal clinical development to seek licensing, sale, or other strategic transactions for its lead product candidate, MAT2203, and its early-stage pipeline.

Products and services

  • The company's primary product candidate is MAT2203 (oral amphotericin B), an antifungal drug designed for the treatment of invasive fungal infections. It also maintains an LNC platform technology intended for the delivery of small molecules and oligonucleotides.

Brands and product families

  • MAT2203 — Lead antifungal product candidate utilizing the LNC platform. Source
  • LNC Platform — Proprietary lipid nanocrystal delivery technology. Source

Customer types

Pharmaceutical and biotechnology companies (potential licensing partners).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Rutgers University — The company maintains a license agreement with Rutgers University regarding intellectual property related to its LNC platform and MAT2203. Source

Business strengths to evaluate

  • Proprietary lipid nanocrystal (LNC) platform delivery technology Source

Business risks and research considerations

  • Significant reduction in workforce and limited capital resources Source
  • Dependence on successful execution of strategic alternatives or licensing transactions Source
  • Regulatory risks associated with FDA approval processes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MTNB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.70
Market capitalization:
1.15M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.31M
Free cash flow:
USD -7.01M
Cash:
USD 761K
Total debt:
USD 6K
EPS:
USD -18.15

What stands out

  • Free cash flow is USD -7.01M, negative for the stored period.
  • The balance sheet shows USD 761K of cash versus USD 6K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 755K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MTNB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MTNB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MTNB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MTNB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MTNB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MTNB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.